Saturday 17 October 2026
Export AAPG’s income statement to Excel — free account
Ascentage Pharma Group International - Unsponsored ADR
AAPG Healthcare Biotechnology
Ascentage Pharma Group International - Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $82.1 million, down 38.9% from fiscal 2024.
15.37
0.68
+4.63%
Follow AAPG
| Older periods | Dec '24 | Jun '25 | Dec '25 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+2 more quarters Free account |
1.26 | 1.54 | 1.79 | 1.22 |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
63.74% | 56.34% | 49.95% | 64.63% | |
Debt/Equity |
6.09 | 2.54 | 1.48 | 3.70 | |
Asset Turnover |
— | — | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | — | 0.00 | 0.00 | |
Capex/Depreciation |
(0.30) | — | (0.36) | 0.00 | |
Intangible Assets out of Total Assets |
0.04 | 0.03 | 0.02 | 0.02 | |
Free Cash Flow per Share |
0.00 | — | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(18.58) | — | (171.84) | (87.41) | |
Working Capital |
42.13 | 93.45 | 186.01 | 60.39 | |
Capital Expenditures |
(3.33) | — | (3.94) | (1.75) | |
Net Current Asset Value |
(119.12) | (64.42) | 45.02 | (56.24) | |
| Other line items | |||||
Quick Ratio |
1.15 | 1.40 | 1.66 | 1.09 | |
Operating CF per Share |
0.00 | — | 0.00 | 0.00 | |
Capex per Share |
0.00 | — | 0.00 | 0.00 | |
Average Receivables |
— | — | 28.12 | 62.68 | |
Average Payables |
— | — | 12.62 | 13.59 | |
Average Inventory |
— | — | 3.16 | 5.48 | |
Average Assets |
— | — | 455.42 | 452.58 | |
Average Common Equity |
— | — | 100.25 | 95.12 | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 |
Columns are period end dates